BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Operating Income
Profit from core operations after operating expenses, before interest and taxes.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$46.18M, compared with -$23.14M a year earlier. Trailing-twelve-month operating income was -$168.86M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -80.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$46.18M-6.4% QoQ
- Last fiscal yearDec 2025
- -$145.82M-80.3% YoY
- LTMMar 2026
- -$168.86M-90.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -99.6% | +100.0% | +199.6 pp |
| 1 year | -80.3% | +100.0% | +180.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (145.82M) USD
- Year-over-year change
- -80.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (145.82M) | -80.3% |
| FY2024 | 2024-12-31 | (80.86M) | -24.8% |
| FY2023 | 2023-12-31 | (64.77M) | -1839985.2% |
| FY2022 | 2022-12-31 | (3.52K) | +91.9% |
| FY2021 | 2021-12-31 | (43.36K) | — |
Operating Income vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -90.7% is the 9th highest of 10, against a peer median of -0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $289.66M USD | +208.4% | — | 41.3% | |
| LTM Mar 2026 | $40.8M USD | +140.7% | — | 17.6% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$73.39M USD | +4.7% | — | 76.2% |
| LTM Mar 2026 | -CHF 84.37M CHF | -8.4% | — | 16741.0% | |
| LTM Mar 2026 | -$96.6M USD | +66.3% | — | 47.1% | |
| LTM Mar 2026 | -$108.21M USD | -0.2% | — | 77.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | -$168.86M USD | -90.7% | — | — |
| LTM Jun 2026 | -$216.08M USD | -69.5% | — | 205.8% | |
| LTM Sep 2026 | -$228.53M USD | -107.1% | — | — | |
| LTM Sep 2026 | -$251.17M USD | -12.6% | — | — | |
| Peer median (excluding BBOT) | — | -0.2% | — | 76.2% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.